DND Technologies, Inc. (DNDT) Stock

About DND Technologies, Inc.

Headquartered in New York City, DND Technologies, Inc. was established in 1997. Operating as a holding company, DND Technologies specializes in the production and sale of diverse specialty balms. Beyond balms, the company is a key manufacturer and distributor of pharmaceutical goods. Its portfolio includes Bioassaygen Gel, formulated to diminish wrinkles and promote natural skin regeneration. The Bioassaygen Cosmetic Mask serves aesthetic enhancement purposes. Additionally, DND offers Bioassaygen Bio-Skin, an innovative skin replacement bandage, and Bioassaygen Delivery Gel, designed to accelerate natural skin renewal. These products reach consumers and businesses through a multi-channel distribution strategy, encompassing wholesale, retail outlets, and e-commerce platforms.

DND Technologies, Inc. is headquartered in US.

DND Technologies, Inc. (DNDT) stock trades at $0.06 with a market capitalization of $184262. The stock is valued at a price-to-earnings (P/E) ratio of 190.33, price-to-book of -0.86, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.06 and $0.20, and currently trades 70.0% below its 52-week high.

On profitability, DND Technologies, Inc. generates a return on equity (ROE) of 2.38%, return on capital employed of 2.36%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.dndtechnologies.com